EcoDrugPlus

Proteasome 20s Subunit Beta 5

Ensembl ID : ENSEEEG00000019394
Gene Symbol: PSMB5
4 Cross references
224 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSEEEG00000002644
Gene Symbol: PSMB6
4 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSEEEG00000001572
Gene Symbol: PSMB6
4 Cross references
183 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSEEEG00000010340
Gene Symbol: PSMB7
4 Cross references
216 Possible Orthologues:

Proteasome 20s Subunit Beta 8a

Ensembl ID : ENSEEEG00000022568
Gene Symbol: PSMB8A
4 Cross references
221 Possible Orthologues:

Proteasome 20s Subunit Beta 9a

Ensembl ID : ENSEEEG00000022604
Gene Symbol: PSMB9A
4 Cross references
211 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSEEEG00000021743
Gene Symbol: PSMD2
4 Cross references
224 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 4a

Ensembl ID : ENSEEEG00000006589
Gene Symbol: PSMD4A
4 Cross references
228 Possible Orthologues:

Proteasome 26s Subunit, Atpase 1a

Ensembl ID : ENSEEEG00000020993
Gene Symbol: PSMC1A
4 Cross references
308 Possible Orthologues:

Proteasome 26s Subunit, Atpase 2

Ensembl ID : ENSEEEG00000010534
Gene Symbol: PSMC2
4 Cross references
233 Possible Orthologues:

Proteasome 26s Subunit, Atpase 3

Ensembl ID : ENSEEEG00000013580
Gene Symbol: PSMC3
4 Cross references
229 Possible Orthologues:

Proteasome 26s Subunit, Atpase 4

Ensembl ID : ENSEEEG00000011541
Gene Symbol: PSMC4
4 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).